<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02100228</url>
  </required_header>
  <id_info>
    <org_study_id>B0661025</org_study_id>
    <secondary_id>CV185-267</secondary_id>
    <secondary_id>2014-001231-36</secondary_id>
    <secondary_id>EMANATE</secondary_id>
    <nct_id>NCT02100228</nct_id>
  </id_info>
  <brief_title>Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion)</brief_title>
  <acronym>EMANATE</acronym>
  <official_title>A Phase Iv Trial To Assess The Effectiveness Of Apixaban Compared With Usual Care Anticoagulation In Subjects With Non-valvular Atrial Fibrillation Undergoing Cardioversion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Some people can develop an abnormal heart beat known as &quot;Atrial fibrillation&quot; or &quot;AF&quot; that
      puts them at risk of developing clots in the heart. Those clots can travel in the blood
      circulation to the brain and cause a brain attack (&quot;a stroke&quot;). To prevent those clots
      forming, blood thinners (anti-coagulants) are used. Apixaban is a blood thinner that works by
      stopping one of the blood substances required for clotting (&quot;Factor Xa&quot;). It is approved and
      used to prevent clots forming in people with &quot;AF&quot;. Other established blood thinners work by
      stopping clotting substances being made, known as &quot;Vitamin K antagonists&quot; or &quot;VKAs&quot;. An
      example of this type is Warfarin (Coumadin). The good effects of all blood thinners are
      preventing clots, and they may also have bad effects of increasing the chance of bleeding.
      People with &quot;AF&quot;, abnormal heart beat, may benefit from changing it back to a normal regular
      rhythm, known medically as &quot;cardioversion&quot;. When this is done, people are currently most
      commonly treated with a &quot;VKA&quot; blood thinner (e.g. warfarin). The purpose of this study is to
      assess the good and bad effects (&quot;efficacy&quot; and &quot;safety&quot;) of apixaban compared with warfarin
      in people with &quot;AF&quot; in whom an early cardioversion is planned.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 14, 2014</start_date>
  <completion_date type="Actual">February 8, 2017</completion_date>
  <primary_completion_date type="Actual">February 8, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Acute Stroke Event</measure>
    <time_frame>Baseline up to 30 days post cardioversion (or up to 90 days after randomization, if cardioversion was not performed within that time frame)</time_frame>
    <description>An acute stroke was defined as a new, important neurological insufficiency of rapid onset that lasted for at least 24 hours and that was not due to a readily identifiable non-vascular cause (like brain tumor or trauma).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Systemic Embolism Event</measure>
    <time_frame>Baseline up to 30 days post cardioversion (or up to 90 days after randomization, if cardioversion was not performed within that time frame)</time_frame>
    <description>Systemic embolism occurred in participant when there was a clinical history consistent with an acute loss of blood flow to a peripheral artery (or arteries), which was supported by evidence of embolism from surgical specimens, autopsy, angiography, or other objective testing.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Major Bleeding Event</measure>
    <time_frame>Baseline up to 30 days post cardioversion (or up to 90 days after randomization, if cardioversion was not performed within that time frame)</time_frame>
    <description>Major bleeding was defined as clinically evident bleeding that was accompanied by one or more of the following: a decrease in hemoglobin of 2 gram per deciliter or more, a transfusion of 2 or more units of packed red blood cells, bleeding that was fatal or bleeding that occurred in at least one of the following critical sites: intracranial, intra-spinal, intraocular (within the corpus of the eye; thus, a conjunctival bleed was not an intraocular bleed), pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Relevant Non-Major Bleeding Events</measure>
    <time_frame>Baseline up to 30 days post cardioversion (or up to 90 days after randomization, if cardioversion was not performed within that time frame)</time_frame>
    <description>Clinically relevant non-major bleeding was defined as the clinically evident bleeding that consisted of any bleeding that compromised hemodynamics, that led to hospitalization, subcutaneous hematoma larger than 25/100 centimeter square if there was a traumatic cause, intramuscular hematoma documented by ultrasonography, epistaxis, gingival bleeding occurred spontaneously, hematuria that was macroscopic and was spontaneous, macroscopic gastrointestinal hemorrhage included at least one episode of melena or hematemesis, rectal blood loss, hemoptysis or any other bleeding type considered to have clinical consequences for a participant, such as medical intervention, the need for unscheduled contact with a physician, or temporary cessation of a study drug, or associated with pain or impairment of activities of daily life.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With All Cause Death</measure>
    <time_frame>Baseline up to 30 days post cardioversion (or up to 90 days after randomization, if cardioversion was not performed within that time frame)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to First Attempt of Cardioversion</measure>
    <time_frame>Baseline up to Day of first attempt of cardioversion procedure (Visit 2, up to 130 days)</time_frame>
    <description>Cardioversion was an effective method of converting an abnormally fast heart rate (tachycardia) or other cardiac arrhythmia to normal rhythm using electricity or drugs. First attempt of cardioversion was defined as the first time the participant was admitted for the cardioversion procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Different Type of Cardioversion Events</measure>
    <time_frame>Baseline up to Day of first attempt of cardioversion procedure (Visit 2, up to 130 days)</time_frame>
    <description>Cardioversion was an effective method of converting an abnormally fast heart rate (tachycardia) or other cardiac arrhythmia to normal rhythm using different type of cardioversion events i.e. electrical and pharmacologic. Electrical cardioversion was a procedure in which an electric current was used to reset the heart's rhythm back to its regular pattern (normal sinus rhythm). Pharmacologic cardioversion, also called chemical cardioversion, used antiarrhythmia medication instead of an electrical shock.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Cardioversion Attempt of Participants</measure>
    <time_frame>Baseline up to Day of first attempt of cardioversion procedure (Visit 2, up to 130 days)</time_frame>
    <description>Cardioversion attempts were defined as the number of times the participant was admitted to hospital for the cardioversion procedure and not the number of attempts during a single hospital admission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Their Rhythm Status</measure>
    <time_frame>Baseline up to Day of first attempt of cardioversion procedure (Visit 2, up to 130 days)</time_frame>
    <description>Rhythm status was further distinguished into sinus rhythm, atrial fibrillation and atrial flutter. Sinus rhythm was defined as a normal heartbeat. Atrial fibrillation was an irregular heartbeat (arrhythmia) that can lead to blood clots, stroke, heart failure and other heart-related complications and atrial flutter was a common abnormal heart rhythm that was usually associated with a fast heart rate (100 or more heart beats per minute).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Hospital Stay of Participants</measure>
    <time_frame>Baseline up to Day of first attempt of cardioversion procedure (Visit 2, up to 130 days)</time_frame>
    <description>Duration of hospital stay was defined as the number of hours from hospital admission to hospital discharge followed by early cardioversion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Used Image Guidance Approach</measure>
    <time_frame>Baseline up to Day of first attempt of cardioversion procedure (Visit 2, up to 130 days)</time_frame>
    <description>An image-guided approach helped cardioversion earlier than the conventional minimum of 3 weeks of anticoagulation that would normally be required prior to cardioversion. Transesophageal echocardiography (TEE or TOE) and computed tomography (CT) were 2 image-guided approaches that were used in this study.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1500</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Apixaban</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Parenteral heparin and/or oral Vitamin K antagonist</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Parenteral heparin and/or locally used oral Vitamin K antagonist e.g. warfarin (excludes other novel oral anticoagulants)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban</intervention_name>
    <description>Oral, 2.5 or 5 mg BID</description>
    <arm_group_label>Apixaban</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Parenteral heparin and/or oral Vitamin K antagonist</intervention_name>
    <description>Parenteral heparin and/or locally used oral Vitamin K antagonist e.g. warfarin (excludes other novel oral anticoagulants)</description>
    <arm_group_label>Parenteral heparin and/or oral Vitamin K antagonist</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with non-valvular atrial fibrillation (as documented by electrocardiogram
             (ECG) at Visit 1) indicated for cardioversion and initiation of anticoagulation in
             accordance with the approved local label. Subjects presenting with atrial flutter with
             no evidence of atrial fibrillation are not eligible for enrolment.

          -  Age ≥18 years (Age ≥ 19 years for Korea only and Age ≥ 20 years for Japan only).

          -  Evidence of a personally signed and dated informed consent document indicating that
             the subject (or their legally-recognized representative) has been informed of all
             pertinent aspects of the study.

          -  The subject is willing to provide contact details for at least one alternate person
             for study staff to contact regarding their whereabouts, should the subject be
             lost-to-follow-up over the course of the study. (Subject to IRB/IEC approval)

          -  Female subjects of childbearing potential must agree to use a highly effective method
             of contraception throughout the study and for at least 28 days after the last dose of
             assigned treatment. A subject is of childbearing potential if, in the opinion of the
             investigator, she is biologically capable of having children and is sexually active.

          -  Subjects who are willing and able to comply with scheduled visits, treatment plan, and
             other study procedures.

        Exclusion Criteria:

          -  Subjects having taken more than 48 hours of an anticoagulant (oral and/or parenteral)
             immediately prior to randomization.

          -  Contraindications to apixaban or usual care (eg, VKA) in accordance with the approved
             local label.

          -  Severe haemodynamically compromised subjects requiring emergent cardioversion.

          -  Patients with hemodynamically significant mitral stenosis, mechanical or biological
             prosthetic valve or valve repair.

          -  Conditions other than atrial fibrillation that require chronic anticoagulation (eg, a
             prosthetic heart valve).

          -  Simultaneous treatment with both aspirin and a thienopyridine (eg, clopidogrel,
             ticlopidine, prasugrel) or simultaneous treatment with both aspirin and ticagrelor.

          -  Pregnant females; breastfeeding females; females of childbearing potential who are
             unwilling or unable to use a highly effective method of contraception as outlined in
             this protocol for the duration of the study and for at least 28 days after last dose
             of investigational product.

          -  Participation in other studies involving investigational drug(s) (Phases 1-4) within
             30 days before the current study begins and/or during study participation. Note:
             Subjects cannot be randomized into this study more than once.

          -  Severe acute or chronic medical or psychiatric condition or laboratory abnormality
             that may increase the risk associated with study participation or investigational
             product administration or may interfere with the interpretation of study results and,
             in the judgment of the investigator, would make the subject inappropriate for entry
             into this study.

          -  Subjects who are investigational site staff members directly involved in the conduct
             of the trial and their family members, site staff members otherwise supervised by the
             Investigator, or subjects who are BMS/Pfizer employees directly involved in the
             conduct of the trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brookwood Medical Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Associates of the Southeast, LLC</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Integrated Medical Services, Inc./IMS Cardiology</name>
      <address>
        <city>Avondale</city>
        <state>Arizona</state>
        <zip>85392</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chula Vista Cardiac Center</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hartford Hospital</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Certified Physician Investigator Research Group LLC</name>
      <address>
        <city>Altamonte Springs</city>
        <state>Florida</state>
        <zip>32714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Heart Specialists</name>
      <address>
        <city>Altamonte Springs</city>
        <state>Florida</state>
        <zip>32714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Chicago Medical Center Investigational Drug Service Pharmacy (office/storage)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Chicago Medical Center Investigational Drug Service Pharmacy</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chicago Medical Research, LLC</name>
      <address>
        <city>Hazel Crest</city>
        <state>Illinois</state>
        <zip>60429</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Franciscan Physician Network-Indiana Heart Physicians</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Franciscan St. Francis Health</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UK Good Samaritan Medical Office Building</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40508-2678</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Good Samaritan Hospital</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40508-3008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky Medical Center Gill Heart Institute</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536-0200</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky Gill Heart Institute</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky HealthCare/Albert. B, Chandler Hospital</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aim Clinic</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiology Outpatient Clinic</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville Clinical Trials Unit</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville Hospital</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robley Rex VA Medical Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alexandria Cardiology Clinic</name>
      <address>
        <city>Alexandria</city>
        <state>Louisiana</state>
        <zip>71301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts Worcester Research Pharmacy</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts Worcester</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William Beaumont Hospital</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abbott Northwestern Hopsital - Allina Health System</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minneapolis Heart Institute Foundation</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Missouri Health Care System</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Missouri Health System, Investigational Drug Serivce</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Missouri Health System</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Luke's Lipid and Diabetes Research Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Electrophysiology Associates</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert Wood Johnson University Hospital</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rutgers Robert Wood Johnson Medical School Cardiovascular Institute</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State University of New York (SUNY) Downstate Medical Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York-Presbyterian/Queens</name>
      <address>
        <city>Flushing</city>
        <state>New York</state>
        <zip>11355</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center/NY Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ProMedica Physicians Cardiology</name>
      <address>
        <city>Oregon</city>
        <state>Ohio</state>
        <zip>43616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ProMedica Toledo Hospital</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ProMedica Physicians Cardiology</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hillcrest Medical Center Pharmacy</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma Heart Institute at Hillcrest Medical Center</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma Heart Institute</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiology Consultants of Philadelphia</name>
      <address>
        <city>Bristol</city>
        <state>Pennsylvania</state>
        <zip>19007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bryn Mawr Hospital</name>
      <address>
        <city>Bryn Mawr</city>
        <state>Pennsylvania</state>
        <zip>19010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bryn Mawr Medical Specialist Association</name>
      <address>
        <city>Bryn Mawr</city>
        <state>Pennsylvania</state>
        <zip>19010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pennsylvania Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Einstein Healthcare Network</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiology consultants of Philadelphia</name>
      <address>
        <city>Yardley</city>
        <state>Pennsylvania</state>
        <zip>19067</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Hospital of Southeast Texas - Beaumont</name>
      <address>
        <city>Beaumont</city>
        <state>Texas</state>
        <zip>77701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeast Texas Cardiology Associates II, L.L.P.</name>
      <address>
        <city>Beaumont</city>
        <state>Texas</state>
        <zip>77702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeast Texas Cardiology Associates II, L.L.P</name>
      <address>
        <city>Beaumont</city>
        <state>Texas</state>
        <zip>77702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeast Texas Clinical Research Center</name>
      <address>
        <city>Beaumont</city>
        <state>Texas</state>
        <zip>77702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Utah Cardiology, PC</name>
      <address>
        <city>Layton</city>
        <state>Utah</state>
        <zip>84041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Associates of Virginia-Bon Secours St. Mary's Hospital</name>
      <address>
        <city>Midlothian</city>
        <state>Virginia</state>
        <zip>23114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Francis Medical Center</name>
      <address>
        <city>Midlothian</city>
        <state>Virginia</state>
        <zip>23114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dominion Cardiovascular Specialists PLLC</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sint-Franciskusziekenhuis</name>
      <address>
        <city>Heusden-Zolder</city>
        <state>Limburg</state>
        <zip>3550</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Ghent</name>
      <address>
        <city>Gent</city>
        <state>Oost-vlaanderen</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <state>Vlaams Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Algemeen Ziekenhuis Klina</name>
      <address>
        <city>Brasschaat</city>
        <zip>2930</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grand Hopital de Charleroi asbl</name>
      <address>
        <city>Gilly</city>
        <zip>6060</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jessa Ziekenhuis-Campus Virga Jesse</name>
      <address>
        <city>Hasselt</city>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Delta</name>
      <address>
        <city>Roeselare</city>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitatires UCL Mont-Godinne</name>
      <address>
        <city>Yvoir</city>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southlake Regional Health Centre</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 2P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cardiologie de Montreal -ICM / Montreal Heart Institute-MHI</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University Health Center</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3G 1A4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regionshospitalet Silkeborg</name>
      <address>
        <city>Silkeborg</city>
        <state>Midtjylland</state>
        <zip>DK-8600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Slagelse Hospital</name>
      <address>
        <city>Slagelse</city>
        <state>Sjaelland</state>
        <zip>DK-4200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sydvestjysk Sygehus Esbjerg</name>
      <address>
        <city>Esbjerg</city>
        <zip>6700</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regionhospitalet Viborg</name>
      <address>
        <city>Viborg</city>
        <zip>DK-8800</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardio Centrum Ludwigsburg Bietigheim</name>
      <address>
        <city>Ludwigsburg</city>
        <state>Baden-württemberg</state>
        <zip>71634</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charitè Campus Mitte/ Medizinische Klinik mit Schwerpunkt Kardiologie und Angiologie</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vivantes -Netzwerk fuer Gesundheit GmbH - Klinikum Neukoelln</name>
      <address>
        <city>Berlin</city>
        <zip>12351</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité - Campus Virchow-Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vivantes Netzwerk fuer Gesundhelt GmbH, Humboldt Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>13509</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Links der Weser gGmbH</name>
      <address>
        <city>Bremen</city>
        <zip>28277</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinisches Versorgungszentrum am Küchwald GmbH</name>
      <address>
        <city>Chemnitz</city>
        <zip>09113</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Coburg gGmbH</name>
      <address>
        <city>Coburg</city>
        <zip>96450</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentrum fuer klinische Pruefungen in der Facharztzentrum Dresden-Neustadt GbR</name>
      <address>
        <city>Dresden</city>
        <zip>01099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxisklinik Herz und Gefäße</name>
      <address>
        <city>Dresden</city>
        <zip>01324</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johanniter-Krankenhaus Rheinhausen GmbH/ Klinik fuer Kardiologie</name>
      <address>
        <city>Duisburg</city>
        <zip>47228</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Nordwest GmbH</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60488</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johann-Wolfgang Goethe-Universitaet</name>
      <address>
        <city>Frankfurt/Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsmedizin Greifswald</name>
      <address>
        <city>Greifswald</city>
        <zip>17475</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg Eppendorf, Universitäres Herzzentrum Hamburg GmbH</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unklinik Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Heidenheim</name>
      <address>
        <city>Heidenheim</city>
        <zip>89522</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Ingolstadt/ Medizinische Klinik I und IV</name>
      <address>
        <city>Ingolstadt</city>
        <zip>85049</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiocenter Rhythmologie</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Leipzig GmbH/ Abteilung für Rhythmologie</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Katholisches Klinikum Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniken Maria Hilf GmbH</name>
      <address>
        <city>Moenchengladbach</city>
        <zip>41063</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Tuebingen</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prof. Dr. med. Werner Jung,Schwarzwald - Baar Klinikum</name>
      <address>
        <city>Villingen-Schwenningen</city>
        <zip>78052</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Josephs-Hospital Warendorf</name>
      <address>
        <city>Warendorf</city>
        <zip>48231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HaEmek Medical Center</name>
      <address>
        <city>Afula</city>
        <zip>18101</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barzilai Medical Center (Cardiology)</name>
      <address>
        <city>Ashkelon</city>
        <zip>78278</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soroka University Medical Centre, Soroka Medical center</name>
      <address>
        <city>Be'er Sheva</city>
        <zip>84101</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hillel Yaffe Medical Center</name>
      <address>
        <city>Hadera</city>
        <zip>38100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Health Care Campus</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lady Davis Carmel Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>34362</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shaare Zedek Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>91031</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah University Hospital - Mount Scopus</name>
      <address>
        <city>Jerusalem</city>
        <zip>91240</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galilee Medical Center</name>
      <address>
        <city>Nahariya</city>
        <zip>22100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center</name>
      <address>
        <city>Petach Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaplan Medical Center</name>
      <address>
        <city>Rehovot</city>
        <zip>76100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ZIV Medical Center</name>
      <address>
        <city>Safed</city>
        <zip>13100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Network Services</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Baruch Padeh Medical Center</name>
      <address>
        <city>Tiberias</city>
        <zip>1528001</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Generale Regionale F. Miulli-Ente Ecclesiastico</name>
      <address>
        <city>Acquaviva Delle Fonti (BA)</city>
        <state>Bari</state>
        <zip>70021</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Campus Biomedico</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>I.R.C.C.S. Ospedale San Raffaele S.r.l.</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona-Umberto I G.M. Lancisi G. Salesi</name>
      <address>
        <city>Torrette Di Ancona</city>
        <state>Marche</state>
        <zip>60020</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presidio Ospedaliero San Donato</name>
      <address>
        <city>Arezzo</city>
        <zip>52100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Careggi, Medicina e Cardiologia Geriatrica</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Cardiologico Monzino</name>
      <address>
        <city>Milano</city>
        <zip>20138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DAI Malattie Cardiovascolari e Respiratorie</name>
      <address>
        <city>Roma</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tosei General Hospital</name>
      <address>
        <city>Seto</city>
        <state>Aichi</state>
        <zip>489-8642</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toho University Ohashi Medical Center</name>
      <address>
        <city>Meguro-ku</city>
        <state>Tokyo</state>
        <zip>153-8515</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka General Medical Center</name>
      <address>
        <city>Osaka</city>
        <zip>558-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nippon Medical School Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>113-8603</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dong-A Unversity Hospital</name>
      <address>
        <city>Busan</city>
        <zip>49201</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Medical Center</name>
      <address>
        <city>Daegu-si</city>
        <zip>700-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yeungnam University Hospital</name>
      <address>
        <city>Deagu</city>
        <zip>705703</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Gwangju</city>
        <zip>501-757</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>120752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital, cardiology and Electrophysiology</name>
      <address>
        <city>Seoul</city>
        <zip>136-705</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea Seoul ST.MARY'S Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>137701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>152-703</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital, Division of Cardiology</name>
      <address>
        <city>Suwon</city>
        <zip>443-380</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brasov Emergency Clinical County Hospital</name>
      <address>
        <city>Brasov</city>
        <zip>500326</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Prof. Dr.C.C. lliescu&quot; Emergency Institute for Cardiovascular Diseases Bucharest</name>
      <address>
        <city>Bucharest</city>
        <zip>022328</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bucharest Emergency University Hospital</name>
      <address>
        <city>Bucharest</city>
        <zip>050098</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cluj-Napoca Rehabilitation Clinical Hospital</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400347</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Craiova Emergency Clinical County Hospital</name>
      <address>
        <city>Craiova</city>
        <zip>200642</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prof.Dr.George I.M. Georgescu Cardiovascular Diseases Institute</name>
      <address>
        <city>Iasi</city>
        <zip>700503</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardio Med SRL</name>
      <address>
        <city>Targu Mures</city>
        <zip>540124</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tirgu Mures Emergency Clinical County Hospital</name>
      <address>
        <city>Tirgu Mures</city>
        <zip>540139</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario San Juan de Alicante</name>
      <address>
        <city>San Juan</city>
        <state>Alicante</state>
        <zip>03550</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Sierrallana</name>
      <address>
        <city>Torrelavega</city>
        <state>Cantabria</state>
        <zip>39300</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consorci Sanitari de Terrassa Hospital de Terrassa</name>
      <address>
        <city>Terrassa</city>
        <state>Cataluna</state>
        <zip>08227</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Infanta Sofía</name>
      <address>
        <city>San Sebastián De Los Reyes</city>
        <state>Madrid</state>
        <zip>28702</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Basurto</name>
      <address>
        <city>Bilbao</city>
        <zip>48013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Maranon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion Jimenez Diaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Danderyds Sjukhus AB</name>
      <address>
        <city>Stockholm</city>
        <state>Sodermanlands LAN</state>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akademiska Sjukhuset I Uppsala/ Kardiologikliniken</name>
      <address>
        <city>Uppsala</city>
        <state>Uppsala IAN</state>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Göteborg</city>
        <zip>41345</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Linkopings Universitetssjukhus Kardiologkliniken</name>
      <address>
        <city>Linkoping</city>
        <zip>581 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitetssjukhuset i Orebro/ Hjartmottagningen</name>
      <address>
        <city>Orebro</city>
        <zip>701 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skelleftea Country Hospital</name>
      <address>
        <city>Skelleftea</city>
        <zip>931 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sodersjukhuset</name>
      <address>
        <city>Stockholm</city>
        <zip>11883</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Romania</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B0661025&amp;StudyName=A%20Phase%20IV%20Trial%20To%20Assess%20The%20Effectiveness%20Of%20Apixaban%20Compared%20With%20Usual%20Care%20Anticoagulation%20In%20Subjects%20With%20Non-Valvular%20Atrial%20Fibrillation%20Undergoing%20Cardioversion</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2014</study_first_submitted>
  <study_first_submitted_qc>March 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2014</study_first_posted>
  <results_first_submitted>January 17, 2018</results_first_submitted>
  <results_first_submitted_qc>March 12, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">April 10, 2018</results_first_posted>
  <last_update_submitted>May 21, 2018</last_update_submitted>
  <last_update_submitted_qc>May 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>apixaban</keyword>
  <keyword>oral anticoagulant</keyword>
  <keyword>non-valvular atrial fibrillation</keyword>
  <keyword>cardioversion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin K</mesh_term>
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Apixaban</mesh_term>
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Anticoagulants</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Apixaban</title>
          <description>Participants with non-valvular atrial fibrillation undergoing cardioversion, received Apixaban orally for 30 days after cardioversion or 90 days after randomization if cardioversion was not performed. The dosing of Apixaban was based on investigator’s judgement as per local label for the prevention of stroke and systemic embolism in participants.</description>
        </group>
        <group group_id="P2">
          <title>Parenteral Heparin/Oral Vitamin K Antagonist (Usual Care)</title>
          <description>Participants with non-valvular atrial fibrillation undergoing cardioversion, received parenteral heparin and/or oral Vitamin K antagonist as usual care, orally for 30 days after cardioversion or 90 days after randomization if cardioversion was not performed. The dosing of the parenteral heparin and Vitamin K antagonist was based on individual participant’s sensitivity to the drug according to the investigators usual practice.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="753">735 treated with Apixaban</participants>
                <participants group_id="P2" count="747">721 treated with Usual Care</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="678"/>
                <participants group_id="P2" count="657"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="90"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative reason</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inclusion/Exclusion criteria not met</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="37"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full analysis set included all randomized participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Apixaban</title>
          <description>Participants with non-valvular atrial fibrillation undergoing cardioversion, received Apixaban orally for 30 days after cardioversion or 90 days after randomization if cardioversion was not performed. The dosing of Apixaban was based on investigator’s judgement as per local label for the prevention of stroke and systemic embolism in participants.</description>
        </group>
        <group group_id="B2">
          <title>Parenteral Heparin/Oral Vitamin K Antagonist (Usual Care)</title>
          <description>Participants with non-valvular atrial fibrillation undergoing cardioversion, received parenteral heparin and/or oral Vitamin K antagonist as usual care, orally for 30 days after cardioversion or 90 days after randomization if cardioversion was not performed. The dosing of the parenteral heparin and Vitamin K antagonist was based on individual participant’s sensitivity to the drug according to the investigators usual practice.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="753"/>
            <count group_id="B2" value="747"/>
            <count group_id="B3" value="1500"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.7" spread="12.19"/>
                    <measurement group_id="B2" value="64.5" spread="12.76"/>
                    <measurement group_id="B3" value="64.6" spread="12.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="248"/>
                    <measurement group_id="B2" value="250"/>
                    <measurement group_id="B3" value="498"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="505"/>
                    <measurement group_id="B2" value="497"/>
                    <measurement group_id="B3" value="1002"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="99"/>
                    <measurement group_id="B3" value="199"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="645"/>
                    <measurement group_id="B2" value="639"/>
                    <measurement group_id="B3" value="1284"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="654"/>
                    <measurement group_id="B2" value="648"/>
                    <measurement group_id="B3" value="1302"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="154"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Acute Stroke Event</title>
        <description>An acute stroke was defined as a new, important neurological insufficiency of rapid onset that lasted for at least 24 hours and that was not due to a readily identifiable non-vascular cause (like brain tumor or trauma).</description>
        <time_frame>Baseline up to 30 days post cardioversion (or up to 90 days after randomization, if cardioversion was not performed within that time frame)</time_frame>
        <population>Full analysis set included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Apixaban</title>
            <description>Participants with non-valvular atrial fibrillation undergoing cardioversion, received Apixaban orally for 30 days after cardioversion or 90 days after randomization if cardioversion was not performed. The dosing of Apixaban was based on investigator’s judgement as per local label for the prevention of stroke and systemic embolism in participants.</description>
          </group>
          <group group_id="O2">
            <title>Parenteral Heparin/Oral Vitamin K Antagonist (Usual Care)</title>
            <description>Participants with non-valvular atrial fibrillation undergoing cardioversion, received parenteral heparin and/or oral Vitamin K antagonist as usual care, orally for 30 days after cardioversion or 90 days after randomization if cardioversion was not performed. The dosing of the parenteral heparin and Vitamin K antagonist was based on individual participant’s sensitivity to the drug according to the investigators usual practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Acute Stroke Event</title>
          <description>An acute stroke was defined as a new, important neurological insufficiency of rapid onset that lasted for at least 24 hours and that was not due to a readily identifiable non-vascular cause (like brain tumor or trauma).</description>
          <population>Full analysis set included all randomized participants.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="753"/>
                <count group_id="O2" value="747"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Display exact confidence limits for relative risk and Fisher’s exact test for comparisons of two proportions.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>This was a descriptive study, and there was no formal pre-defined hypothesis testing.</non_inferiority_desc>
            <p_value>0.0151</p_value>
            <p_value_desc>nominal p-value</p_value_desc>
            <method>Fisher Exact</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.0000</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0000</ci_lower_limit>
            <ci_upper_limit>0.6425</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Systemic Embolism Event</title>
        <description>Systemic embolism occurred in participant when there was a clinical history consistent with an acute loss of blood flow to a peripheral artery (or arteries), which was supported by evidence of embolism from surgical specimens, autopsy, angiography, or other objective testing.</description>
        <time_frame>Baseline up to 30 days post cardioversion (or up to 90 days after randomization, if cardioversion was not performed within that time frame)</time_frame>
        <population>Full analysis set included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Apixaban</title>
            <description>Participants with non-valvular atrial fibrillation undergoing cardioversion, received Apixaban orally for 30 days after cardioversion or 90 days after randomization if cardioversion was not performed. The dosing of Apixaban was based on investigator’s judgement as per local label for the prevention of stroke and systemic embolism in participants.</description>
          </group>
          <group group_id="O2">
            <title>Parenteral Heparin/Oral Vitamin K Antagonist (Usual Care)</title>
            <description>Participants with non-valvular atrial fibrillation undergoing cardioversion, received parenteral heparin and/or oral Vitamin K antagonist as usual care, orally for 30 days after cardioversion or 90 days after randomization if cardioversion was not performed. The dosing of the parenteral heparin and Vitamin K antagonist was based on individual participant’s sensitivity to the drug according to the investigators usual practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Systemic Embolism Event</title>
          <description>Systemic embolism occurred in participant when there was a clinical history consistent with an acute loss of blood flow to a peripheral artery (or arteries), which was supported by evidence of embolism from surgical specimens, autopsy, angiography, or other objective testing.</description>
          <population>Full analysis set included all randomized participants.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="753"/>
                <count group_id="O2" value="747"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Major Bleeding Event</title>
        <description>Major bleeding was defined as clinically evident bleeding that was accompanied by one or more of the following: a decrease in hemoglobin of 2 gram per deciliter or more, a transfusion of 2 or more units of packed red blood cells, bleeding that was fatal or bleeding that occurred in at least one of the following critical sites: intracranial, intra-spinal, intraocular (within the corpus of the eye; thus, a conjunctival bleed was not an intraocular bleed), pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal.</description>
        <time_frame>Baseline up to 30 days post cardioversion (or up to 90 days after randomization, if cardioversion was not performed within that time frame)</time_frame>
        <population>Safety data set included all treated participants (randomized participants who received at least one dose of study drug).</population>
        <group_list>
          <group group_id="O1">
            <title>Apixaban</title>
            <description>Participants with non-valvular atrial fibrillation undergoing cardioversion, received Apixaban orally for 30 days after cardioversion or 90 days after randomization if cardioversion was not performed. The dosing of Apixaban was based on investigator’s judgement as per local label for the prevention of stroke and systemic embolism in participants.</description>
          </group>
          <group group_id="O2">
            <title>Parenteral Heparin/Oral Vitamin K Antagonist (Usual Care)</title>
            <description>Participants with non-valvular atrial fibrillation undergoing cardioversion, received parenteral heparin and/or oral Vitamin K antagonist as usual care, orally for 30 days after cardioversion or 90 days after randomization if cardioversion was not performed. The dosing of the parenteral heparin and Vitamin K antagonist was based on individual participant’s sensitivity to the drug according to the investigators usual practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Major Bleeding Event</title>
          <description>Major bleeding was defined as clinically evident bleeding that was accompanied by one or more of the following: a decrease in hemoglobin of 2 gram per deciliter or more, a transfusion of 2 or more units of packed red blood cells, bleeding that was fatal or bleeding that occurred in at least one of the following critical sites: intracranial, intra-spinal, intraocular (within the corpus of the eye; thus, a conjunctival bleed was not an intraocular bleed), pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal.</description>
          <population>Safety data set included all treated participants (randomized participants who received at least one dose of study drug).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="735"/>
                <count group_id="O2" value="721"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Display exact confidence limits for relative risk and Fisher’s exact test for comparisons of two proportions.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>This was a descriptive study, and there was no formal pre-defined hypothesis testing.</non_inferiority_desc>
            <p_value>0.3378</p_value>
            <p_value_desc>nominal p-value</p_value_desc>
            <method>Fisher Exact</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.4905</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.1046</ci_lower_limit>
            <ci_upper_limit>2.0678</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinically Relevant Non-Major Bleeding Events</title>
        <description>Clinically relevant non-major bleeding was defined as the clinically evident bleeding that consisted of any bleeding that compromised hemodynamics, that led to hospitalization, subcutaneous hematoma larger than 25/100 centimeter square if there was a traumatic cause, intramuscular hematoma documented by ultrasonography, epistaxis, gingival bleeding occurred spontaneously, hematuria that was macroscopic and was spontaneous, macroscopic gastrointestinal hemorrhage included at least one episode of melena or hematemesis, rectal blood loss, hemoptysis or any other bleeding type considered to have clinical consequences for a participant, such as medical intervention, the need for unscheduled contact with a physician, or temporary cessation of a study drug, or associated with pain or impairment of activities of daily life.</description>
        <time_frame>Baseline up to 30 days post cardioversion (or up to 90 days after randomization, if cardioversion was not performed within that time frame)</time_frame>
        <population>Safety data set included all treated participants (randomized participants who received at least one dose of study drug).</population>
        <group_list>
          <group group_id="O1">
            <title>Apixaban</title>
            <description>Participants with non-valvular atrial fibrillation undergoing cardioversion, received Apixaban orally for 30 days after cardioversion or 90 days after randomization if cardioversion was not performed. The dosing of Apixaban was based on investigator’s judgement as per local label for the prevention of stroke and systemic embolism in participants.</description>
          </group>
          <group group_id="O2">
            <title>Parenteral Heparin/Oral Vitamin K Antagonist (Usual Care)</title>
            <description>Participants with non-valvular atrial fibrillation undergoing cardioversion, received parenteral heparin and/or oral Vitamin K antagonist as usual care, orally for 30 days after cardioversion or 90 days after randomization if cardioversion was not performed. The dosing of the parenteral heparin and Vitamin K antagonist was based on individual participant’s sensitivity to the drug according to the investigators usual practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Relevant Non-Major Bleeding Events</title>
          <description>Clinically relevant non-major bleeding was defined as the clinically evident bleeding that consisted of any bleeding that compromised hemodynamics, that led to hospitalization, subcutaneous hematoma larger than 25/100 centimeter square if there was a traumatic cause, intramuscular hematoma documented by ultrasonography, epistaxis, gingival bleeding occurred spontaneously, hematuria that was macroscopic and was spontaneous, macroscopic gastrointestinal hemorrhage included at least one episode of melena or hematemesis, rectal blood loss, hemoptysis or any other bleeding type considered to have clinical consequences for a participant, such as medical intervention, the need for unscheduled contact with a physician, or temporary cessation of a study drug, or associated with pain or impairment of activities of daily life.</description>
          <population>Safety data set included all treated participants (randomized participants who received at least one dose of study drug).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="735"/>
                <count group_id="O2" value="721"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Display exact confidence limits for relative risk and Fisher’s exact test for comparisons of two proportions.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>This was a descriptive study, and there was no formal pre-defined hypothesis testing.</non_inferiority_desc>
            <p_value>0.6851</p_value>
            <p_value_desc>nominal p-value</p_value_desc>
            <method>Fisher Exact</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.8300</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.3433</ci_lower_limit>
            <ci_upper_limit>1.8916</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With All Cause Death</title>
        <time_frame>Baseline up to 30 days post cardioversion (or up to 90 days after randomization, if cardioversion was not performed within that time frame)</time_frame>
        <population>Full analysis set included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Apixaban</title>
            <description>Participants with non-valvular atrial fibrillation undergoing cardioversion, received Apixaban orally for 30 days after cardioversion or 90 days after randomization if cardioversion was not performed. The dosing of Apixaban was based on investigator’s judgement as per local label for the prevention of stroke and systemic embolism in participants.</description>
          </group>
          <group group_id="O2">
            <title>Parenteral Heparin/Oral Vitamin K Antagonist (Usual Care)</title>
            <description>Participants with non-valvular atrial fibrillation undergoing cardioversion, received parenteral heparin and/or oral Vitamin K antagonist as usual care, orally for 30 days after cardioversion or 90 days after randomization if cardioversion was not performed. The dosing of the parenteral heparin and Vitamin K antagonist was based on individual participant’s sensitivity to the drug according to the investigators usual practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Cause Death</title>
          <population>Full analysis set included all randomized participants.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="753"/>
                <count group_id="O2" value="747"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Display exact confidence limits for relative risk and Fisher’s exact test for comparisons of two proportions.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>This was a descriptive study, and there was no formal pre-defined hypothesis testing.</non_inferiority_desc>
            <p_value>&gt;0.9999</p_value>
            <p_value_desc>nominal p-value</p_value_desc>
            <method>Fisher Exact</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.9841</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.1866</ci_lower_limit>
            <ci_upper_limit>53.9968</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Attempt of Cardioversion</title>
        <description>Cardioversion was an effective method of converting an abnormally fast heart rate (tachycardia) or other cardiac arrhythmia to normal rhythm using electricity or drugs. First attempt of cardioversion was defined as the first time the participant was admitted for the cardioversion procedure.</description>
        <time_frame>Baseline up to Day of first attempt of cardioversion procedure (Visit 2, up to 130 days)</time_frame>
        <population>Full analysis set included all randomized participants. Here, &quot;N&quot; (number of participants analyzed) signifies participants who were evaluable for this specified outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Apixaban</title>
            <description>Participants with non-valvular atrial fibrillation undergoing cardioversion, received Apixaban orally for 30 days after cardioversion or 90 days after randomization if cardioversion was not performed. The dosing of Apixaban was based on investigator’s judgement as per local label for the prevention of stroke and systemic embolism in participants.</description>
          </group>
          <group group_id="O2">
            <title>Parenteral Heparin/Oral Vitamin K Antagonist (Usual Care)</title>
            <description>Participants with non-valvular atrial fibrillation undergoing cardioversion, received parenteral heparin and/or oral Vitamin K antagonist as usual care, orally for 30 days after cardioversion or 90 days after randomization if cardioversion was not performed. The dosing of the parenteral heparin and Vitamin K antagonist was based on individual participant’s sensitivity to the drug according to the investigators usual practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Attempt of Cardioversion</title>
          <description>Cardioversion was an effective method of converting an abnormally fast heart rate (tachycardia) or other cardiac arrhythmia to normal rhythm using electricity or drugs. First attempt of cardioversion was defined as the first time the participant was admitted for the cardioversion procedure.</description>
          <population>Full analysis set included all randomized participants. Here, &quot;N&quot; (number of participants analyzed) signifies participants who were evaluable for this specified outcome measure.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="510"/>
                <count group_id="O2" value="511"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1" upper_limit="93"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1" upper_limit="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Different Type of Cardioversion Events</title>
        <description>Cardioversion was an effective method of converting an abnormally fast heart rate (tachycardia) or other cardiac arrhythmia to normal rhythm using different type of cardioversion events i.e. electrical and pharmacologic. Electrical cardioversion was a procedure in which an electric current was used to reset the heart's rhythm back to its regular pattern (normal sinus rhythm). Pharmacologic cardioversion, also called chemical cardioversion, used antiarrhythmia medication instead of an electrical shock.</description>
        <time_frame>Baseline up to Day of first attempt of cardioversion procedure (Visit 2, up to 130 days)</time_frame>
        <population>Full analysis set included all randomized participants. Here &quot;N&quot; signifies number of participants who were evaluable for this specified outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Apixaban</title>
            <description>Participants with non-valvular atrial fibrillation undergoing cardioversion, received Apixaban orally for 30 days after cardioversion or 90 days after randomization if cardioversion was not performed. The dosing of Apixaban was based on investigator’s judgement as per local label for the prevention of stroke and systemic embolism in participants.</description>
          </group>
          <group group_id="O2">
            <title>Parenteral Heparin/Oral Vitamin K Antagonist (Usual Care)</title>
            <description>Participants with non-valvular atrial fibrillation undergoing cardioversion, received parenteral heparin and/or oral Vitamin K antagonist as usual care, orally for 30 days after cardioversion or 90 days after randomization if cardioversion was not performed. The dosing of the parenteral heparin and Vitamin K antagonist was based on individual participant’s sensitivity to the drug according to the investigators usual practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Different Type of Cardioversion Events</title>
          <description>Cardioversion was an effective method of converting an abnormally fast heart rate (tachycardia) or other cardiac arrhythmia to normal rhythm using different type of cardioversion events i.e. electrical and pharmacologic. Electrical cardioversion was a procedure in which an electric current was used to reset the heart's rhythm back to its regular pattern (normal sinus rhythm). Pharmacologic cardioversion, also called chemical cardioversion, used antiarrhythmia medication instead of an electrical shock.</description>
          <population>Full analysis set included all randomized participants. Here &quot;N&quot; signifies number of participants who were evaluable for this specified outcome measure.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="496"/>
                <count group_id="O2" value="494"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Electrical</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="461"/>
                    <measurement group_id="O2" value="464"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pharmacologic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Cardioversion Attempt of Participants</title>
        <description>Cardioversion attempts were defined as the number of times the participant was admitted to hospital for the cardioversion procedure and not the number of attempts during a single hospital admission.</description>
        <time_frame>Baseline up to Day of first attempt of cardioversion procedure (Visit 2, up to 130 days)</time_frame>
        <population>Full analysis set included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Apixaban</title>
            <description>Participants with non-valvular atrial fibrillation undergoing cardioversion, received Apixaban orally for 30 days after cardioversion or 90 days after randomization if cardioversion was not performed. The dosing of Apixaban was based on investigator’s judgement as per local label for the prevention of stroke and systemic embolism in participants.</description>
          </group>
          <group group_id="O2">
            <title>Parenteral Heparin/Oral Vitamin K Antagonist (Usual Care)</title>
            <description>Participants with non-valvular atrial fibrillation undergoing cardioversion, received parenteral heparin and/or oral Vitamin K antagonist as usual care, orally for 30 days after cardioversion or 90 days after randomization if cardioversion was not performed. The dosing of the parenteral heparin and Vitamin K antagonist was based on individual participant’s sensitivity to the drug according to the investigators usual practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Cardioversion Attempt of Participants</title>
          <description>Cardioversion attempts were defined as the number of times the participant was admitted to hospital for the cardioversion procedure and not the number of attempts during a single hospital admission.</description>
          <population>Full analysis set included all randomized participants.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="753"/>
                <count group_id="O2" value="747"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No Cardioversion Attempt</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="234"/>
                    <measurement group_id="O2" value="224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Cardioversion Attempt</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="488"/>
                    <measurement group_id="O2" value="496"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than 2 Cardioversion Attempts</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Their Rhythm Status</title>
        <description>Rhythm status was further distinguished into sinus rhythm, atrial fibrillation and atrial flutter. Sinus rhythm was defined as a normal heartbeat. Atrial fibrillation was an irregular heartbeat (arrhythmia) that can lead to blood clots, stroke, heart failure and other heart-related complications and atrial flutter was a common abnormal heart rhythm that was usually associated with a fast heart rate (100 or more heart beats per minute).</description>
        <time_frame>Baseline up to Day of first attempt of cardioversion procedure (Visit 2, up to 130 days)</time_frame>
        <population>Safety data set included all treated participants (randomized participants who received at least one dose of study drug). Here &quot;N&quot; signifies number of participants who were evaluable for this specified outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Apixaban</title>
            <description>Participants with non-valvular atrial fibrillation undergoing cardioversion, received Apixaban orally for 30 days after cardioversion or 90 days after randomization if cardioversion was not performed. The dosing of Apixaban was based on investigator’s judgement as per local label for the prevention of stroke and systemic embolism in participants.</description>
          </group>
          <group group_id="O2">
            <title>Parenteral Heparin/Oral Vitamin K Antagonist (Usual Care)</title>
            <description>Participants with non-valvular atrial fibrillation undergoing cardioversion, received parenteral heparin and/or oral Vitamin K antagonist as usual care, orally for 30 days after cardioversion or 90 days after randomization if cardioversion was not performed. The dosing of the parenteral heparin and Vitamin K antagonist was based on individual participant’s sensitivity to the drug according to the investigators usual practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Their Rhythm Status</title>
          <description>Rhythm status was further distinguished into sinus rhythm, atrial fibrillation and atrial flutter. Sinus rhythm was defined as a normal heartbeat. Atrial fibrillation was an irregular heartbeat (arrhythmia) that can lead to blood clots, stroke, heart failure and other heart-related complications and atrial flutter was a common abnormal heart rhythm that was usually associated with a fast heart rate (100 or more heart beats per minute).</description>
          <population>Safety data set included all treated participants (randomized participants who received at least one dose of study drug). Here &quot;N&quot; signifies number of participants who were evaluable for this specified outcome measure.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="719"/>
                <count group_id="O2" value="712"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Normal Sinus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Atrial Fibrillation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="715"/>
                    <measurement group_id="O2" value="704"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Atrial Flutter</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Hospital Stay of Participants</title>
        <description>Duration of hospital stay was defined as the number of hours from hospital admission to hospital discharge followed by early cardioversion.</description>
        <time_frame>Baseline up to Day of first attempt of cardioversion procedure (Visit 2, up to 130 days)</time_frame>
        <population>Full analysis set included all randomized participants. Here &quot;N&quot; signifies number of participants who were evaluable for this specified outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Apixaban</title>
            <description>Participants with non-valvular atrial fibrillation undergoing cardioversion, received Apixaban orally for 30 days after cardioversion or 90 days after randomization if cardioversion was not performed. The dosing of Apixaban was based on investigator’s judgement as per local label for the prevention of stroke and systemic embolism in participants.</description>
          </group>
          <group group_id="O2">
            <title>Parenteral Heparin/Oral Vitamin K Antagonist (Usual Care)</title>
            <description>Participants with non-valvular atrial fibrillation undergoing cardioversion, received parenteral heparin and/or oral Vitamin K antagonist as usual care, orally for 30 days after cardioversion or 90 days after randomization if cardioversion was not performed. The dosing of the parenteral heparin and Vitamin K antagonist was based on individual participant’s sensitivity to the drug according to the investigators usual practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Hospital Stay of Participants</title>
          <description>Duration of hospital stay was defined as the number of hours from hospital admission to hospital discharge followed by early cardioversion.</description>
          <population>Full analysis set included all randomized participants. Here &quot;N&quot; signifies number of participants who were evaluable for this specified outcome measure.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="330"/>
                <count group_id="O2" value="346"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.36" lower_limit="0.4" upper_limit="747.0"/>
                    <measurement group_id="O2" value="49.47" lower_limit="0.6" upper_limit="709.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Used Image Guidance Approach</title>
        <description>An image-guided approach helped cardioversion earlier than the conventional minimum of 3 weeks of anticoagulation that would normally be required prior to cardioversion. Transesophageal echocardiography (TEE or TOE) and computed tomography (CT) were 2 image-guided approaches that were used in this study.</description>
        <time_frame>Baseline up to Day of first attempt of cardioversion procedure (Visit 2, up to 130 days)</time_frame>
        <population>Full analysis set included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Apixaban</title>
            <description>Participants with non-valvular atrial fibrillation undergoing cardioversion, received Apixaban orally for 30 days after cardioversion or 90 days after randomization if cardioversion was not performed. The dosing of Apixaban was based on investigator’s judgement as per local label for the prevention of stroke and systemic embolism in participants.</description>
          </group>
          <group group_id="O2">
            <title>Parenteral Heparin/Oral Vitamin K Antagonist (Usual Care)</title>
            <description>Participants with non-valvular atrial fibrillation undergoing cardioversion, received parenteral heparin and/or oral Vitamin K antagonist as usual care, orally for 30 days after cardioversion or 90 days after randomization if cardioversion was not performed. The dosing of the parenteral heparin and Vitamin K antagonist was based on individual participant’s sensitivity to the drug according to the investigators usual practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Used Image Guidance Approach</title>
          <description>An image-guided approach helped cardioversion earlier than the conventional minimum of 3 weeks of anticoagulation that would normally be required prior to cardioversion. Transesophageal echocardiography (TEE or TOE) and computed tomography (CT) were 2 image-guided approaches that were used in this study.</description>
          <population>Full analysis set included all randomized participants.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="753"/>
                <count group_id="O2" value="747"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="383"/>
                    <measurement group_id="O2" value="399"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From baseline up to 30 days after cardioversion or 90 days after randomization, if cardioversion was not performed</time_frame>
      <desc>Same event may appear as adverse event (AE) and serious adverse event (SAE), what is presented are distinct events. Event may be categorized as serious in 1 participant and as non-serious in another participant or 1 participant may have experienced both serious and non-serious event during study. Safety data set included all treated participants.</desc>
      <group_list>
        <group group_id="E1">
          <title>Apixaban</title>
          <description>Participants with non-valvular atrial fibrillation undergoing cardioversion, received Apixaban orally for 30 days after cardioversion or 90 days after randomization if cardioversion was not performed. The dosing of Apixaban was based on investigator’s judgement as per local label for the prevention of stroke and systemic embolism in participants.</description>
        </group>
        <group group_id="E2">
          <title>Parenteral Heparin/Oral Vitamin K Antagonist (Usual Care)</title>
          <description>Participants with non-valvular atrial fibrillation undergoing cardioversion, received parenteral heparin and/or oral Vitamin K antagonist as usual care, orally for 30 days after cardioversion or 90 days after randomization if cardioversion was not performed. The dosing of the parenteral heparin and Vitamin K antagonist was based on individual participant’s sensitivity to the drug according to the investigators usual practice.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 19.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="100" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="112" subjects_at_risk="721"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>HAEMORRHAGIC ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="721"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>ANGINA PECTORIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>ARTERIOSCLEROSIS CORONARY ARTERY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>ATRIAL FLUTTER</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>ATRIAL THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>ATRIOVENTRICULAR BLOCK COMPLETE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>ATRIOVENTRICULAR DISSOCIATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>BRADYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE CONGESTIVE</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>CARDIO-RESPIRATORY ARREST</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>CARDIOGENIC SHOCK</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>CONGESTIVE CARDIOMYOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>ISCHAEMIC CARDIOMYOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>MITRAL VALVE INCOMPETENCE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>MITRAL VALVE PROLAPSE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL ISCHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>PALPITATIONS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>PERICARDIAL EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>PERICARDITIS CONSTRICTIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>SINUS ARREST</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>SINUS NODE DYSFUNCTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>TACHYARRHYTHMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>TACHYCARDIA INDUCED CARDIOMYOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>TRICUSPID VALVE INCOMPETENCE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="721"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>ADENOMATOUS POLYPOSIS COLI</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>HYPERTROPHIC CARDIOMYOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="721"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>ADRENAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>TOXIC NODULAR GOITRE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="721"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>DUODENAL ULCER HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>ENTEROCOLITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>FEMORAL HERNIA INCARCERATED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>GASTRIC ULCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>HAEMATEMESIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>HAEMATOCHEZIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>LARGE INTESTINE PERFORATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>MELAENA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>MESENTERIC PANNICULITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>OEDEMATOUS PANCREATITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>OESOPHAGITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>PEPTIC ULCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>PEPTIC ULCER HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>RECTAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="721"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>MUCOSAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>MULTIPLE ORGAN DYSFUNCTION SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>NON-CARDIAC CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>SUDDEN DEATH</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="721"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>DRUG-INDUCED LIVER INJURY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>HEPATIC CONGESTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="721"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>DRUG HYPERSENSITIVITY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="721"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>ABSCESS LIMB</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>ESCHERICHIA URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>INFECTIVE EXACERBATION OF CHRONIC OBSTRUCTIVE AIRWAYS DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>INTESTINAL SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>LUNG INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>SEPTIC SHOCK</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>UROSEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="721"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ARTERIAL BYPASS THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>EYE INJURY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>FEMUR FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>HEAD INJURY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>OVERDOSE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>RADIUS FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>TOXICITY TO VARIOUS AGENTS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>TRAUMATIC INTRACRANIAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>VASCULAR PSEUDOANEURYSM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="721"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>COMPUTERISED TOMOGRAM CORONARY ARTERY ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>FUNCTIONAL RESIDUAL CAPACITY DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>HEPATIC ENZYME INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>INTERNATIONAL NORMALISED RATIO ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>INTERNATIONAL NORMALISED RATIO INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>WEIGHT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="721"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>HYPOKALAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="721"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>FLANK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="721"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>ACUTE LEUKAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>ADENOCARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>BREAST CANCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>ENDOMETRIAL CANCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>METASTASES TO BONE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>PROSTATE CANCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>SQUAMOUS CELL CARCINOMA OF SKIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="721"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>BRAIN INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>CEREBRAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>CEREBRAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>CEREBROVASCULAR ACCIDENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>DEMENTIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>PRESYNCOPE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>SEIZURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>TRANSIENT ISCHAEMIC ATTACK</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="721"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="721"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE KIDNEY INJURY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>HAEMATURIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>POSTRENAL FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>RENAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="721"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>VAGINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="721"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE PULMONARY OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>ATELECTASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>MEDIASTINAL CYST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>MEDIASTINAL HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>PNEUMOTHORAX</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>PULMONARY CONGESTION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>PULMONARY HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>PULMONARY OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>PULMONARY SARCOIDOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="721"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>DECUBITUS ULCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>DIABETIC FOOT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>PETECHIAE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>SUBCUTANEOUS EMPHYSEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="721"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>ARTERIAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>ARTERIOVENOUS FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>HYPERTENSIVE CRISIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="721"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 19.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="101" subjects_at_risk="721"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>ATRIAL THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="721"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>INTERNATIONAL NORMALISED RATIO ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>INTERNATIONAL NORMALISED RATIO INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="721"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="735"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="721"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The prioritization of outcome measures is not mentioned in the study documents (Statistical Analysis Plan and Protocol). The prioritization of outcome measures is based on team’s discretion.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

